2. Academic Validation
  3. Discovery of novel 1-azoniabicyclo[2.2.2]octane muscarinic acetylcholine receptor antagonists

Discovery of novel 1-azoniabicyclo[2.2.2]octane muscarinic acetylcholine receptor antagonists

  • J Med Chem. 2009 Apr 23;52(8):2493-505. doi: 10.1021/jm801601v.
Dramane I Lainé 1,  Brent McCleland,  Sonia Thomas,  Christopher Neipp,  Brian Underwood,  Jeremy Dufour,  Katherine L Widdowson,  Michael R Palovich,  Frank E Blaney,  James J Foley,  Edward F Webb,  Mark A Luttmann,  Miriam Burman,  Kristen Belmonte,  Michael Salmon
Affiliations

Affiliation

  • 1 GlaxoSmithKline, Respiratory CEDD, 709 Swedeland Road, P.O. Box 1539, King of Prussia, Pennsylvania 19406-0939, USA. dramane.i.laine@gsk.com
PMID: 19317446 DOI: 10.1021/jm801601v
Abstract

A novel 4-hydroxyl(diphenyl)methyl substituted quinuclidine series was discovered as a very promising class of muscarinic antagonists. The structure-activity relationships of the connectivity of the diphenyl moiety to the quinuclidine core and around the ring nitrogen side chain are described. Computational docking studies using an homology model of the M(3) receptor readily explained the observed structure-activity relationship of the various compounds. Compound 14o was identified as a very potent, slowly reversible M(3) antagonist with a very long in vivo duration of bronchoprotection.

Figures
Products